- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05884814
Timing of Resistance Exercise in Type 1 Diabetes (T-REX)
July 27, 2023 updated by: Dr. Ebaa Al Ozairi, Dasman Diabetes Institute
Timing of Resistance Exercise, Glucose Control and Exercise Adaptations in People With Type 1 Diabetes: a Randomised-controlled Trial
The aims of the current study are
- to compare the effects of acute morning and afternoon resistance exercise on blood glucose levels in people with type 1 diabetes.
- to compare the effects of morning and afternoon resistance exercise training on cardiometabolic health outcomes in people with type 1 diabetes
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ebaa AlOzairi, MBChB
- Phone Number: +965 22242999
- Email: ebaa.alozairi@dasmaninstitute.rog
Study Locations
-
-
-
Kuwait City, Kuwait, 15462
- Recruiting
- Dasman Diabetes Institute
-
Contact:
- Ebaa AlOZairi
-
Principal Investigator:
- Ebaa AlOzairi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Physician confirmed type 1 diabetes for at least 1 year
- Stable insulin therapy for 3 months prior to the study
Exclusion Criteria:
- BMI of 45 or higher
- BP of 160/100mmHg or higher
- autonomic neuropathy
- severe proliferative retinopathy
- joint or limb injuries preventing weight-bearing activity
- autonomic neuropathy
- severe proliferative retinopathy
- any other medical condition that prevents participants from exercising safely.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
Habitual physical activity
|
Participants will be asked to maintain their normal activity levels
|
Active Comparator: Morning exercise
Exercise training between 6-10am
|
Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
|
Active Comparator: Afternoon exercise
Exercise training between 4-8pm
|
Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in muscle strength
Time Frame: Change from baseline to 12 weeks
|
Sum of one repetition maximum for the 7 resistance exercise
|
Change from baseline to 12 weeks
|
Change in interstitial glucose time in range
Time Frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Interstitial glucose time in range (3.9-10mmol/L) measured via continuous glucose monitoring
|
Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in appendicular skeletal muscle mass
Time Frame: Change from baseline to 12 weeks
|
Measured by DEXA
|
Change from baseline to 12 weeks
|
Change in whole body fat mass
Time Frame: Change from baseline to 12 weeks
|
Measured by DEXA
|
Change from baseline to 12 weeks
|
Change in physical function
Time Frame: Change from baseline to 12 weeks
|
Measured by the short performance physical battery
|
Change from baseline to 12 weeks
|
Change in HbA1c
Time Frame: Change from baseline to 12 weeks
|
HbA1c concentration
|
Change from baseline to 12 weeks
|
Change in interstitial glucose average
Time Frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Interstitial average glucose measured via continuous glucose monitoring
|
Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Change in interstitial glucose variability
Time Frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Interstitial glucose variability measured via continuous glucose monitoring
|
Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Change in interstitial glucose time in hypoglycaemia
Time Frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Interstitial glucose time in range (<3.9mmol/L) measured via continuous glucose monitoring
|
Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Change in interstitial glucose time in hyperglycaemia
Time Frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Interstitial glucose time in range (>10mmol/L) measured via continuous glucose monitoring
|
Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2023
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
May 10, 2023
First Submitted That Met QC Criteria
May 22, 2023
First Posted (Actual)
June 1, 2023
Study Record Updates
Last Update Posted (Actual)
July 28, 2023
Last Update Submitted That Met QC Criteria
July 27, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RA HM-2023-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Habitual physical activity levels
-
Loughborough UniversityCompletedInflammation | Physical Activity | Central ObesityUnited Kingdom
-
Palo Alto Veterans Institute for ResearchW.L.Gore & Associates; Boston Scientific Corporation; Abbott; Cook Group IncorporatedRecruitingIntermittent Claudication | Peripheral Artery DiseaseUnited States
-
University of BirminghamMaastricht UniversityCompletedSedentary LifestyleUnited Kingdom
-
Büşra SarıkayaCompleted
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedPhysical ActivityGermany
-
University of TorontoRecruitingSarcopenia | Aging | Sedentary Behavior | Amino Acids | Dietary ProteinCanada
-
Queen's University, BelfastCompleted
-
University of ValenciaGeneralitat ValencianaRecruiting
-
University of TorontoRecruitingPhysical Inactivity | Resistance Exercise | Amino Acids | Dietary ProteinCanada
-
Dasman Diabetes InstituteRecruiting